Using the technique, scientists were able to grow a pure, self-renewing population of stem cells specific to the human foregut, which is the upper section of the human digestive system. These cells could then be developed further to produce liver or pancreatic cells.
You are here
Coverage of the latest news and updates from the field of stem cells.
"We are excited to begin the next phase of this neural stem cell trial, further evaluating safety precautions while increasing both the number of injections and cells transplanted in ALS patients," says Jonathan Glass, M.D., director of the Emory ALS Center and principal investigator of the Emory
“If you think of a cell as a drug factory, what we’re doing is targeting cell-based drug factories to damaged or diseased tissues where the cells can produce drugs at high enough levels to have a therapeutic effect,” said Jeffrey Karp, Ph.D.
The research, by scientists at The Institute of Cancer Research (ICR), London, provides the latest evidence that despite having identical DNA, sister stem cells can display considerable differences in their molecular characteristics.
The Institute for Regenerative Medicine at Wake Forest University School of Medicine (Wake Forest Baptist Medical Center) has been selected to lead the second phase of the Armed Forces Institute of Regenerative Medicine (AFIRM).
The results, which are reported online Sept. 17 in The EMBO Journal, could eventually lead to ways to repair damaged insulin-producing beta cells or pancreatic duct cells.
The finding, which involves a mysterious protein called MBD3, might help facilitate the production of stem cells for medical use as well as advance our understanding of the process by which adult cells can revert back into their embryonic state.
The family of proteins, called Wnts, send signals from the outside to the inside of a cell, inducing a cellular response crucial for many aspects of embryonic development — including stem cell differentiation — as well as for normal functioning of the adult brain.
Manuel Serrano, Ph.D., director of CNIO’s Molecular Oncology Program and head of the Tumoural Suppression Laboratory, led the study. It was supported by Manuel Manzanares, Ph.D., and his team from the Spanish National Cardiovascular Research Centre.
The study, led by Steven R. Houser, Ph.D., FAHA, director of Tulane’s School of Medicine's Cardiovascular Research Center (CVRC), could lead to an “off the rack” source of stem cells for regenerating cardiac tissue following a heart attack.